Eintrag weiter verarbeiten
Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis.
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Blood, 114, 2009, 22, S. 2871-2871 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Lamm, Wolfgang Willenbacher, Wolfgang Zojer, Niklas Müldür, Ercan Ludwig, Heinz Lang, Alois Zielinski, Christoph C Drach, Johannes Lamm, Wolfgang Willenbacher, Wolfgang Zojer, Niklas Müldür, Ercan Ludwig, Heinz Lang, Alois Zielinski, Christoph C Drach, Johannes |
|---|---|
| author |
Lamm, Wolfgang Willenbacher, Wolfgang Zojer, Niklas Müldür, Ercan Ludwig, Heinz Lang, Alois Zielinski, Christoph C Drach, Johannes |
| spellingShingle |
Lamm, Wolfgang Willenbacher, Wolfgang Zojer, Niklas Müldür, Ercan Ludwig, Heinz Lang, Alois Zielinski, Christoph C Drach, Johannes Blood Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. Cell Biology Hematology Immunology Biochemistry |
| author_sort |
lamm, wolfgang |
| spelling |
Lamm, Wolfgang Willenbacher, Wolfgang Zojer, Niklas Müldür, Ercan Ludwig, Heinz Lang, Alois Zielinski, Christoph C Drach, Johannes 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v114.22.2871.2871 <jats:title>Abstract</jats:title> <jats:p>Abstract 2871</jats:p> <jats:p>Poster Board II-847</jats:p> <jats:sec> <jats:title>Introduction:</jats:title> <jats:p>AL amyloidosis is characterized by misfolding of structurally unstable light chains that form deposits in various organs thereby causing impaired organ function. Treatment of AL amyloidosis remains challenging and is primarily directed towards the underlying abnormal plasma cell clone. Novel agents with proven efficacy in multiple myeloma like the proteasome inhibitor bortezomib have also shown initial promising results in patients with AL amyloidosis, but its value needs to be further established. In this retrospective analysis, we have collected data regarding efficacy and tolerability of treatment with bortezomib plus dexamethasone in patients with AL amyloidosis.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods:</jats:title> <jats:p>25 patients with histologically proven systemic AL amyloidosis were included in this analysis. All patients received bortezomib at a standard dose of 1.3mg/m2 (days 1, 4, 8, 11 of a 3-week cycle) in combination with dexamethasone (8mg to 20mg administered on the day of bortezomib and the day after). Routine clinical and laboratory parameters including evaluation were obtained on a monthly basis.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Patients (male n=13, female n=12) were at a median age of 57 years (range 42-83), and 17 patients (68%) received bortezomib/dexamethasone as their first line treatment. The majority of patients had an ECOG performance status of < 2. Twelve patients (48%) had only one organ involved, whereas > 2 organs were involved in 6 patients (24%). Organs most frequently involved were kidneys (100%), heart (28%), liver (12%) and the gastrointestinal tract (12%). At the time of analysis, a median of 3 cycles of bortezomib/dexamethasone (range, 1 to 8) have been administered. A hematologic response was observed in 14 patients (56%) including 5 patients (20%) qualifying for a complete response (CR). All CR patients received bortezomib/dexamethasone as their first line treatment, and parameters of organ function also improved in these patients. Median overall survival has not yet been reached after a median follow-up of 12 months. Grade 3 and 4 toxicities were rare and consisted predominantly of transient thrombocytopenia. Grade 2 neurotoxicity was observed in 24% of patients. Other grade 1/2 toxicities observed at higher frequencies included hypotension (16%), edema (16%), and fatigue (12%).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>Our results confirm the activity of bortezomib/dexamethasone in patients with AL amyloidosis (hematologic response rate 56% including a 20% CR rate).</jats:p> </jats:sec> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>Ludwig: Celgene: Honoraria; Mundipharma: Honoraria; AMGEN: Honoraria; Ortho-Biotech : Honoraria; Janssen-Cilag: Research Funding; Roche: Honoraria.</jats:p> </jats:sec> Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. Blood |
| doi_str_mv |
10.1182/blood.v114.22.2871.2871 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE0LjIyLjI4NzEuMjg3MQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE0LjIyLjI4NzEuMjg3MQ |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 |
| imprint |
American Society of Hematology, 2009 |
| imprint_str_mv |
American Society of Hematology, 2009 |
| issn |
1528-0020 0006-4971 |
| issn_str_mv |
1528-0020 0006-4971 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
lamm2009efficacyofthecombinationofbortezomibanddexamethasoneinsystemicalamyloidosis |
| publishDateSort |
2009 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_unstemmed |
Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_full |
Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_fullStr |
Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_full_unstemmed |
Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_short |
Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_sort |
efficacy of the combination of bortezomib and dexamethasone in systemic al amyloidosis. |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood.v114.22.2871.2871 |
| publishDate |
2009 |
| physical |
2871-2871 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Abstract 2871</jats:p>
<jats:p>Poster Board II-847</jats:p>
<jats:sec>
<jats:title>Introduction:</jats:title>
<jats:p>AL amyloidosis is characterized by misfolding of structurally unstable light chains that form deposits in various organs thereby causing impaired organ function. Treatment of AL amyloidosis remains challenging and is primarily directed towards the underlying abnormal plasma cell clone. Novel agents with proven efficacy in multiple myeloma like the proteasome inhibitor bortezomib have also shown initial promising results in patients with AL amyloidosis, but its value needs to be further established. In this retrospective analysis, we have collected data regarding efficacy and tolerability of treatment with bortezomib plus dexamethasone in patients with AL amyloidosis.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Patients and Methods:</jats:title>
<jats:p>25 patients with histologically proven systemic AL amyloidosis were included in this analysis. All patients received bortezomib at a standard dose of 1.3mg/m2 (days 1, 4, 8, 11 of a 3-week cycle) in combination with dexamethasone (8mg to 20mg administered on the day of bortezomib and the day after). Routine clinical and laboratory parameters including evaluation were obtained on a monthly basis.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>Patients (male n=13, female n=12) were at a median age of 57 years (range 42-83), and 17 patients (68%) received bortezomib/dexamethasone as their first line treatment. The majority of patients had an ECOG performance status of < 2. Twelve patients (48%) had only one organ involved, whereas > 2 organs were involved in 6 patients (24%). Organs most frequently involved were kidneys (100%), heart (28%), liver (12%) and the gastrointestinal tract (12%). At the time of analysis, a median of 3 cycles of bortezomib/dexamethasone (range, 1 to 8) have been administered. A hematologic response was observed in 14 patients (56%) including 5 patients (20%) qualifying for a complete response (CR). All CR patients received bortezomib/dexamethasone as their first line treatment, and parameters of organ function also improved in these patients. Median overall survival has not yet been reached after a median follow-up of 12 months. Grade 3 and 4 toxicities were rare and consisted predominantly of transient thrombocytopenia. Grade 2 neurotoxicity was observed in 24% of patients. Other grade 1/2 toxicities observed at higher frequencies included hypotension (16%), edema (16%), and fatigue (12%).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion:</jats:title>
<jats:p>Our results confirm the activity of bortezomib/dexamethasone in patients with AL amyloidosis (hematologic response rate 56% including a 20% CR rate).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Disclosures:</jats:title>
<jats:p>Ludwig: Celgene: Honoraria; Mundipharma: Honoraria; AMGEN: Honoraria; Ortho-Biotech : Honoraria; Janssen-Cilag: Research Funding; Roche: Honoraria.</jats:p>
</jats:sec> |
| container_issue |
22 |
| container_start_page |
2871 |
| container_title |
Blood |
| container_volume |
114 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792321989823692806 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T11:10:48.17Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Efficacy+of+the+Combination+of+Bortezomib+and+Dexamethasone+in+Systemic+AL+Amyloidosis.&rft.date=2009-11-20&genre=article&issn=1528-0020&volume=114&issue=22&spage=2871&epage=2871&pages=2871-2871&jtitle=Blood&atitle=Efficacy+of+the+Combination+of+Bortezomib+and+Dexamethasone+in+Systemic+AL+Amyloidosis.&aulast=Drach&aufirst=Johannes&rft_id=info%3Adoi%2F10.1182%2Fblood.v114.22.2871.2871&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792321989823692806 |
| author | Lamm, Wolfgang, Willenbacher, Wolfgang, Zojer, Niklas, Müldür, Ercan, Ludwig, Heinz, Lang, Alois, Zielinski, Christoph C, Drach, Johannes |
| author_facet | Lamm, Wolfgang, Willenbacher, Wolfgang, Zojer, Niklas, Müldür, Ercan, Ludwig, Heinz, Lang, Alois, Zielinski, Christoph C, Drach, Johannes, Lamm, Wolfgang, Willenbacher, Wolfgang, Zojer, Niklas, Müldür, Ercan, Ludwig, Heinz, Lang, Alois, Zielinski, Christoph C, Drach, Johannes |
| author_sort | lamm, wolfgang |
| container_issue | 22 |
| container_start_page | 2871 |
| container_title | Blood |
| container_volume | 114 |
| description | <jats:title>Abstract</jats:title> <jats:p>Abstract 2871</jats:p> <jats:p>Poster Board II-847</jats:p> <jats:sec> <jats:title>Introduction:</jats:title> <jats:p>AL amyloidosis is characterized by misfolding of structurally unstable light chains that form deposits in various organs thereby causing impaired organ function. Treatment of AL amyloidosis remains challenging and is primarily directed towards the underlying abnormal plasma cell clone. Novel agents with proven efficacy in multiple myeloma like the proteasome inhibitor bortezomib have also shown initial promising results in patients with AL amyloidosis, but its value needs to be further established. In this retrospective analysis, we have collected data regarding efficacy and tolerability of treatment with bortezomib plus dexamethasone in patients with AL amyloidosis.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods:</jats:title> <jats:p>25 patients with histologically proven systemic AL amyloidosis were included in this analysis. All patients received bortezomib at a standard dose of 1.3mg/m2 (days 1, 4, 8, 11 of a 3-week cycle) in combination with dexamethasone (8mg to 20mg administered on the day of bortezomib and the day after). Routine clinical and laboratory parameters including evaluation were obtained on a monthly basis.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Patients (male n=13, female n=12) were at a median age of 57 years (range 42-83), and 17 patients (68%) received bortezomib/dexamethasone as their first line treatment. The majority of patients had an ECOG performance status of < 2. Twelve patients (48%) had only one organ involved, whereas > 2 organs were involved in 6 patients (24%). Organs most frequently involved were kidneys (100%), heart (28%), liver (12%) and the gastrointestinal tract (12%). At the time of analysis, a median of 3 cycles of bortezomib/dexamethasone (range, 1 to 8) have been administered. A hematologic response was observed in 14 patients (56%) including 5 patients (20%) qualifying for a complete response (CR). All CR patients received bortezomib/dexamethasone as their first line treatment, and parameters of organ function also improved in these patients. Median overall survival has not yet been reached after a median follow-up of 12 months. Grade 3 and 4 toxicities were rare and consisted predominantly of transient thrombocytopenia. Grade 2 neurotoxicity was observed in 24% of patients. Other grade 1/2 toxicities observed at higher frequencies included hypotension (16%), edema (16%), and fatigue (12%).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>Our results confirm the activity of bortezomib/dexamethasone in patients with AL amyloidosis (hematologic response rate 56% including a 20% CR rate).</jats:p> </jats:sec> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>Ludwig: Celgene: Honoraria; Mundipharma: Honoraria; AMGEN: Honoraria; Ortho-Biotech : Honoraria; Janssen-Cilag: Research Funding; Roche: Honoraria.</jats:p> </jats:sec> |
| doi_str_mv | 10.1182/blood.v114.22.2871.2871 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE0LjIyLjI4NzEuMjg3MQ |
| imprint | American Society of Hematology, 2009 |
| imprint_str_mv | American Society of Hematology, 2009 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1 |
| issn | 1528-0020, 0006-4971 |
| issn_str_mv | 1528-0020, 0006-4971 |
| language | English |
| last_indexed | 2024-03-01T11:10:48.17Z |
| match_str | lamm2009efficacyofthecombinationofbortezomibanddexamethasoneinsystemicalamyloidosis |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 2871-2871 |
| publishDate | 2009 |
| publishDateSort | 2009 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Lamm, Wolfgang Willenbacher, Wolfgang Zojer, Niklas Müldür, Ercan Ludwig, Heinz Lang, Alois Zielinski, Christoph C Drach, Johannes 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v114.22.2871.2871 <jats:title>Abstract</jats:title> <jats:p>Abstract 2871</jats:p> <jats:p>Poster Board II-847</jats:p> <jats:sec> <jats:title>Introduction:</jats:title> <jats:p>AL amyloidosis is characterized by misfolding of structurally unstable light chains that form deposits in various organs thereby causing impaired organ function. Treatment of AL amyloidosis remains challenging and is primarily directed towards the underlying abnormal plasma cell clone. Novel agents with proven efficacy in multiple myeloma like the proteasome inhibitor bortezomib have also shown initial promising results in patients with AL amyloidosis, but its value needs to be further established. In this retrospective analysis, we have collected data regarding efficacy and tolerability of treatment with bortezomib plus dexamethasone in patients with AL amyloidosis.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods:</jats:title> <jats:p>25 patients with histologically proven systemic AL amyloidosis were included in this analysis. All patients received bortezomib at a standard dose of 1.3mg/m2 (days 1, 4, 8, 11 of a 3-week cycle) in combination with dexamethasone (8mg to 20mg administered on the day of bortezomib and the day after). Routine clinical and laboratory parameters including evaluation were obtained on a monthly basis.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Patients (male n=13, female n=12) were at a median age of 57 years (range 42-83), and 17 patients (68%) received bortezomib/dexamethasone as their first line treatment. The majority of patients had an ECOG performance status of < 2. Twelve patients (48%) had only one organ involved, whereas > 2 organs were involved in 6 patients (24%). Organs most frequently involved were kidneys (100%), heart (28%), liver (12%) and the gastrointestinal tract (12%). At the time of analysis, a median of 3 cycles of bortezomib/dexamethasone (range, 1 to 8) have been administered. A hematologic response was observed in 14 patients (56%) including 5 patients (20%) qualifying for a complete response (CR). All CR patients received bortezomib/dexamethasone as their first line treatment, and parameters of organ function also improved in these patients. Median overall survival has not yet been reached after a median follow-up of 12 months. Grade 3 and 4 toxicities were rare and consisted predominantly of transient thrombocytopenia. Grade 2 neurotoxicity was observed in 24% of patients. Other grade 1/2 toxicities observed at higher frequencies included hypotension (16%), edema (16%), and fatigue (12%).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>Our results confirm the activity of bortezomib/dexamethasone in patients with AL amyloidosis (hematologic response rate 56% including a 20% CR rate).</jats:p> </jats:sec> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>Ludwig: Celgene: Honoraria; Mundipharma: Honoraria; AMGEN: Honoraria; Ortho-Biotech : Honoraria; Janssen-Cilag: Research Funding; Roche: Honoraria.</jats:p> </jats:sec> Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. Blood |
| spellingShingle | Lamm, Wolfgang, Willenbacher, Wolfgang, Zojer, Niklas, Müldür, Ercan, Ludwig, Heinz, Lang, Alois, Zielinski, Christoph C, Drach, Johannes, Blood, Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis., Cell Biology, Hematology, Immunology, Biochemistry |
| title | Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_full | Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_fullStr | Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_full_unstemmed | Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_short | Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| title_sort | efficacy of the combination of bortezomib and dexamethasone in systemic al amyloidosis. |
| title_unstemmed | Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood.v114.22.2871.2871 |